Registration and prospectus / Drugs Made In America Acquisition Corp. | Tables in SEC filings

DMAA Drugs Made In America Acquisition Corp.

IPO registration (amended)

The pro forma NTBV per share after this offering for each of the redemption scenarios is calculated as follows:

	No Redemption				25% of Maximum Redemption				50% of Maximum Redemption				75% of Maximum Redemption				Maximum Redemption
	Without Over-Allotment		With Over-Allotment		Without Over-Allotment		With Over-Allotment		Without Over-Allotment		With Over-Allotment		Without Over-Allotment		With Over-Allotment		Without Over-Allotment		With Over-Allotment
Numerator:
Net tangible book deficit before this offering	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)	$	(588,903)
Net proceeds from this offering and the sale of the private placement units(1)		202,100,000		232,250,000		202,100,000		232,250,000		202,100,000		232,250,000		202,100,000		232,250,000		202,100,000		232,250,000
Plus: Offering costs accrued for or paid in advance, excluded from tangible book value		424,044		424,044		424,044		424,044		424,044		424,044		424,044		424,044		424,044		424,044
Less: Deferred underwriting commissions(2)		(6,000,000)		(6,900,000)		(6,000,000)		(6,900,000)		(6,000,000)		(6,900,000)		(6,000,000)		(6,900,000)		(6,000,000)		(6,900,000)
Less: Over-allotment liability		(418,300)		—		(418,300)		—		(418,300)		—		(418,300)		—		(418,300)		—
Less: Amounts paid for redemptions(3)		—		—		(50,250,000)		(57,787,500)		(100,500,000)		(115,575,000)		(150,750,000)		(173,362,500)		(201,000,000)		(231,150,000)
Total		195,516,841		225,185,141		145,266,841		167,397,641		95,016,841		109,610,141		44,766,841		51,822,641		(5,483,159)		(5,964,859)

Denominator:
Ordinary shares outstanding prior to this offering		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143		9,857,143
Ordinary shares forfeited if over-allotment is not exercised		(1,285,714)		—		(1,285,714)		—		(1,285,714)		—		(1,285,714)		—		(1,285,714)		—
Ordinary shares offered		20,000,000		23,000,000		20,000,000		23,000,000		20,000,000		23,000,000		20,000,000		23,000,000		20,000,000		23,000,000
Shares underlying IPO Rights		2,500,000		2,875,000		2,500,000		2,875,000		2,500,000		2,875,000		2,500,000		2,875,000		2,500,000		2,875,000
Private placement shares		400,000		430,000		400,000		430,000		400,000		430,000		400,000		430,000		400,000		430,000
Shares underlying Private Placement Rights		50,000		53,750		50,000		53,750		50,000		53,750		50,000		53,750		50,000		53,750
Representative Shares		200,000		230,000		200,000		230,000		200,000		230,000		200,000		230,000		200,000		230,000
Less: Ordinary shares redeemed		—		—		(5,000,000)		(5,750,000)		(10,000,000)		(11,500,000)		(15,000,000)		(17,250,000)		(20,000,000)		(23,000,000)
Total		31,721,429		36,445,893		26,721,429		30,695,893		21,721,429		24,945,893		16,721,429		19,195,893		11,721,429		13,445,893

	Per Unit		Total
Public offering price	$	10.00	$	200,000,000
Underwriting discounts and commissions(1)	$	0.35	$	7,000,000
Proceeds, before expenses, to us	$	9.65	$	193,000,000

	September 30, 2024
	Actual		As Adjusted
Working capital (deficiency)(1)	$	(588,903)	$	516,841
Total assets(2)	$	426,139	$	201,935,141
Total liabilities(3)	$	590,998	$	6,418,300
Value of ordinary shares subject to possible redemption(4)	$	—	$	201,000,000
Shareholders’ deficit(5)	$	(164,859)	$	(5,483,159)

	Before Offering			After Offering
Name and Address of Beneficial Owner(1)	Number of Shares Beneficially Owned	Approximate Percentage of Outstanding Ordinary Shares		Number of Shares Beneficially Owned	Approximate Percentage of Outstanding Ordinary Shares
Drugs Made In America Acquisition LLC(2)	9,857,143	100	%	8,571,429	29.4	%
Lynn Stockwell(2)	9,857,143	100	%	8,571,429	29.4	%
Glenn Worman	—	—		100,000	*
Catherine Do	—	—		100,000	*
G. Sridhar Prasad	—	—		100,000	*
Myron W. Shulgan	—	—		100,000	*
All officers, directors and director nominees as a group (five individuals)(2)	9,857,143	100	%	8,971,429	30.8	%

	Without Over-Allotment Option			Over-Allotment Option Exercised
Gross proceeds
Gross proceeds from units offered to public(1)	$	200,000,000		$	230,000,000
Gross proceeds from private units offered in the private placement		4,000,000			4,300,000
Total gross proceeds	$	204,000,000		$	234,300,000
Estimated offering expenses(2)
Underwriting commissions (excluding deferred portion)(3)	$	1,000,000		$	1,150,000
Legal fees and expenses		400,000			400,000
Accounting fees and expenses		180,000			180,000
Printing and road show expenses		50,000			50,000
SEC/FINRA expenses		79,000			79,000
Nasdaq listing and filing fees		80,000			80,000
Miscellaneous expenses(4)		111,000			111,000
Total estimated offering expenses (other than underwriting commissions)	$	900,000		$	900,000
Proceeds after estimated offering expenses	$	202,100,000		$	232,250,000
Held in trust account(3)	$	201,000,000		$	231,150,000
% of public offering size		100.0	%		100.0	%
Not held in trust account(2)	$	1,100,000		$	1,100,000

Table search / Registration and prospectus / Drugs Made In America Acquisition Corp.

132 results

Top filers

Top filing types

Recent filing years